Mesoblast Secures Regenerative Advanced Therapy Designation From US FDA for Cellular Therapy Product; Shares Hit Near 3.5-Year High
Mesoblast Secures Regenerative Advanced Therapy Designation From US FDA for Cellular Therapy Product; Shares Hit Near 3.5-Year High
美索博科獲美國FDA細胞治療產品再生先進治療設計認定；股價創近3.5年新高
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間